Gastro-Intestinal Cancer Trial: ECOG-ACRIN E7208 (Iowa Cancer Specialists)

A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab, in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy

Objective

The purpose of this study is to determine what good or bad effects the drug, ramucirumab, may have on patients who have colon or rectal cancer that has spread to other organs or has come back locally with the first choice of treatment. The study is also trying to determine whether it is safe and effective for patients to receive this treatment.

Irinotecan and cetuximab are standard treatments for patients who have metastatic colon or rectal cancer, who have already received one previous chemotherapy that is no longer working, and do not have a specific type of mutation (alteration) of the K-ras gene in their tumor. Ramucirumab is an experimental  drug that has been found to block a pathway that allows tumors to grow in animals and humans. Ramucirumab is an FDA approved drug for the treatment of gastric and GE cancers however is not yet approved for treatment of colorectal cancer.  It is unknown if adding a drug of this type to a standard second line therapy for colorectal cancer is beneficial.

For more information on this trial, visit the National Cancer Institute.

IRB Protocol Number
ECOG-ACRIN E7208
Principal Investigator(s)
George Kovach

Clinical Trial Categories

  • Cancer
  • Gastro-Intestinal
Sponsor(s)
Eastern Cooperative Oncology Group
Contact
Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com

Location

  • Cancer Care Institute
    1351 West Central Park
    Pavilion 1, 1st Floor
    Davenport, IA 52804
    Main: 563-421-1900
    Alternate: 800-446-6088
    Fax: 563-421-1938

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email